Antibody response after a single dose of ChAdOx1-nCOV (Covishield) vaccine in subjects with prior SARS-CoV2 infection: Is a single dose sufficient?
Borkakoty, B.; Sarmah, M. D.; Bhattacharjee, C. K.; Bali, N.; Gogoi, G.
Show abstract
It is crucial to know whether a single dose of vaccine against SARS-CoV-2 is sufficient to elicit immune response in previously infected people in India. A total of 121 participants (baseline seropositive 46 and seronegative 75) were included to study the immune response to ChAdOx1-nCOV (Covishield) vaccine in previously infected or uninfected people. IgG antibodies were estimated at three different time intervals, i.e. pre-vaccination, 25-35 days post 1st vaccination and 25-35 days post 2nd vaccination. The IgG antibody titre was significantly high among previous seropositive subjects with single dose of vaccine compared to seronegative group with both doses of vaccine respectively (4.59{+/-}1.04 vs 3.08{+/-}1.22, p-value: <0.0001). In conclusion, a single dose of Covishield(R) vaccine might be sufficient to induce an effective immune responsein subjects with prior SARS-CoV2 infection. Stratifying vacinees based on their SARS-CoV2 IgG antibody titre before vaccination would help in meeting the increasing vaccine demand and could be effective to circumvent further wave of the pandemic in India.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Immunogenicity and safety of Biological Es CORBEVAX vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD or COVAXIN: A Prospective double-blind randomised phase III clinical study 95%
- Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2 94%
- The Global case-fatality rate of COVID-19 has been declining disproportionately between top vaccinated countries and the rest of the world 92%
Similar papers in this journal
- Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians 96%
- Understanding COVID-19 vaccine hesitancy in Pakistan: The paradigm of Confidence, Convenience, and Complacency; A Cross-sectional study 95%
- Acceptance and Attitudes Toward COVID-19 Vaccines: A Cross-Sectional Study from Jordan 95%
Similar papers in this journal
- SARS-CoV-2 seroprevalence in Delhi, India - September-October 2021 – a population based seroepidemiological study 96%
- Breakthrough infection with SARS-CoV-2 and its predictors among healthcare workers in a medical college and hospital complex in Delhi, India 94%
- Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent? 94%
Similar papers in this journal
- Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac 95%
- Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models 94%
- A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines 94%
Similar papers in this journal
- ChAdOx1 n-COV-19 Vaccine Side Effects Among Health Care Workers in Trinidad and Tobago 95%
- Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine 95%
- COVID-19 vaccine hesitancy worldwide: a systematic review of vaccine acceptance rates 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.